Carl Zeiss Meditec


CZM’s eye attractiveness fades

18/06/24 -"Surprisingly, CZM slashed its full-year guidance yesterday. Greater Chinese exposure (marred by VBP roll-out delays and softer start to the summer peak season) and delayed interest rate cuts weighed ..."

Pages
63
Language
English
Published on
18/06/24
You may also be interested by these reports :
27/08/26
Elekta’s Q1 sales fell short of expectations, although profitability surpassed forecasts. The top line declined due to underperformance in Solutions, ...

27/08/26
EssilorLuxottica (EL) (BUY; France) share price peaked in late 2026 and has shed 40% ytd. No small feat for a stock that used to be worth more than ...

20/08/26
GN reported a weak quarter, impacted by challenging market conditions and subdued consumer sentiment. The decline in the top line was primarily ...

19/08/26
S&N Q2/H1 26 print disappointed: revenue missed consensus, forcing management to cut FY26 revenue growth guidance to 4% from 6%, while Orthopaedics ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO